CNO Financial Group Inc. research snapshot
CNO AI stock analysis currently views CNO Financial Group as a middle-market insurance holding company with established brands, an expanding senior demographic tailwind, and solid free cash flow generation. The counterweight is a weak profit margin, high debt-to-equity ratio, a historical bankruptcy legacy (Conseco, 2002), and a valuation that already prices in much of the recent operational improvement. The AI view is a cautious watch-and-monitor framework, not a precise price prediction or personal investment recommendation.
Current price
$51.96
Market cap
$4.85 billion
AI score
52 / 100
Rating
Moderate-quality insurer with a legacy bankruptcy overhang, meaningful debt leverage, and narrow valuation upside at the current multiple
Trend status
The stock hit a 52-week high of $53.55 and is trading near the high end of its historic range
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | CNO sells Medicare supplement, supplemental health, life insurance, and annuities to middle-income pre-retirees and retirees under the Bankers Life, Colonial Penn, and Washington National brands. | Medium |
| Moat | Brand recognition (Colonial Penn, Bankers Life), direct-to-consumer distribution, and an aging U.S. demographic provide some insulation, but pricing power and switching costs are limited versus larger peers such as MetLife, Prudential, and Unum. | Medium-low |
| Management | CEO Gary C. Bhojwani has led the company through the post-Conseco restructuring era. Capital allocation is focused on debt reduction, dividends, and share buybacks. Management has navigated the legacy overhang but the track record on organic growth is modest. | Medium |
| Financial trend | Revenue TTM of $4.51B with net income of $245.5M. Q1 2026 revenue was $1.03B and net income $101.3M. Profit margin is low at 5.44% and ROE is 9.76%, reflecting the capital-intensive insurance model. | Medium |
| Valuation | Priced at 20.95x trailing earnings, 1.94x book value, and 1.13x sales. FCF yield is attractive at 21.25% on levered FCF of $1.03B, but the high debt/equity ratio of 172% raises questions about capital structure efficiency. | Medium |
| Technical trend | The stock is near its 52-week high of $53.55, up roughly 22% YTD. Momentum is positive but the stock is approaching overbought territory near the resistance level. | Medium-low |
| Risk level | Elevated by high debt leverage, thin GAAP profit margins, interest rate and claims experience sensitivity, regulatory exposure, and the overhang from the 2002 Conseco Chapter 11 bankruptcy. | Medium |
| AI confidence | Financial data is well documented; forward return scenarios remain highly conditional on interest rates, claims experience, debt management, and market multiple expansion. | Medium data confidence |
| Investment certainty | The insurance business is understandable and cash generative, but the entry price at 20.95x earnings for a mid-single-digit grower with high leverage leaves a thin margin of safety. | Medium-low |
CNO AI stock forecast
The CNO AI stock forecast is a scenario framework rather than a promised target. A three-year calculation using TTM EPS of $2.48, a July 2026 reference price of $51.96, and distinct growth and multiple assumptions produces a wide range of outcomes.
About $68 to $70
More likely if CNO sustains mid-to-high single digit earnings growth, successfully reduces debt leverage, benefits from favorable claims experience and interest income, and the market re-rates the stock toward a 22x multiple reflecting improved confidence in the business model.
About $50 to $53
More likely if EPS compounds around 5%, debt reduction progresses gradually, the dividend grows modestly, valuation holds around 18x earnings, and the stock remains range-bound at roughly current prices.
About $33 to $36
More likely if claims deterioration, adverse interest rate movements, recessionary pressure on the middle-income customer base, or debt covenant issues emerge, compressing the multiple to 14x or below.
CNO AI technical analysis
CNO AI technical analysis uses the latest independently available price data through July 10, 2026. The stock closed at $51.96 on July 10 and traded as high as $52.71 in after-hours. The stock hit a 52-week high of $53.55 during the current run. These levels are a price-action framework, not a live chart feed, and should be refreshed before any trading decision.
| Level | Value | Why it matters |
|---|---|---|
| Current price reference | $51.96 close on July 10; $52.71 after hours | Yahoo Finance real-time data, last checked July 12, 2026. |
| 52-week range | $35.24 to $53.55 | Wide range reflecting the significant recovery from 2025 lows. |
| Immediate support | $48 to $50 | The round-number zone that held during June pullbacks. |
| Lower support | $42 to $44 | The area that acted as resistance-turned-support during Q1 2026 consolidation. |
| Near resistance | $53.50 to $55.00 | The 52-week high at $53.55 is the immediate ceiling. A clean breakout above this level with volume would be technically constructive. |
| 50-day moving average | Estimated near $48 to $50 | Estimated from available price history; use a current chart before relying on this indicator. |
| 200-day moving average | Not independently verified | Use a current chart before relying on this long-term trend signal. |
| Momentum | Positive, near overbought | The stock has rallied roughly 47% from the 52-week low of $35.24. RSI is likely elevated. |
| Volume | Average volume 784,830 shares | Moderate liquidity; larger trades may move the stock. |
| Volatility marker | $35.24 to $53.55 over 52 weeks | A meaningful range that reflects both business recovery and general market conditions. |
| Invalidation | Sustained close below $44 | A break of the Q1 2026 consolidation support zone would weaken the technical recovery setup. |
CNO AI trading strategy
The CNO AI trading strategy is a rules-based research framework, not personal advice. It pairs insurance-sector and cash-flow evidence with observable price levels and predefined invalidation conditions.
Watch for a sustained close above $53.55 (52-week high) on above-average volume. Confirm with evidence of improving operating margins, stable claims experience, and debt reduction progress in quarterly results.
Treat a reversal below $50 or a failed breakout above the 52-week high as a rules-based signal to reduce exposure.
If CNO pulls back to the $44 to $48 zone, compare the price action with quarterly earnings trends, net investment income stability, and leverage ratios before assuming support will hold.
Do not average down solely because the stock has fallen. Size risk for further downside given the elevated debt and historically low GAAP margins.
Track quarterly revenue trends by segment, net income, operating margin, combined ratio, debt-to-equity, book value per share, dividend coverage, and share buyback execution.
Reassess the thesis if operating margins compress, debt ratios increase, the dividend is cut, or the macroeconomic outlook for the middle-income insurance customer deteriorates meaningfully.
Investment research summary
CNO Financial Group sells health insurance, life insurance, and annuity products to middle-income pre-retiree and retired Americans. Customers pay for financial protection, Medicare supplement coverage, and guaranteed income products distributed through Bankers Life agents, Colonial Penn direct marketing, and Washington National supplemental channels.
Its moat rests on established brand names (Colonial Penn, Bankers Life), direct-to-consumer marketing reach, licensed agent networks, and an aging U.S. population driving demand for Medicare supplement and senior insurance products. It is not wide: larger competitors like MetLife, Prudential, and Unum have greater scale, lower cost of capital, and diversified product lines.
The thesis can fail if claims experience deteriorates, interest income falls, the middle-income customer base comes under economic pressure, debt service constraints limit capital allocation flexibility, or the historical Conseco bankruptcy overhang prevents a valuation multiple expansion.
Gary C. Bhojwani has been CEO since the post-Conseco era, overseeing the corporate rebranding and balance sheet restructuring. The key management tests are disciplined capital allocation between debt reduction, dividends, and stock buybacks; maintaining stable underwriting margins in Medicare supplement and supplemental health; and organic growth in the core middle-income customer segment.
The insurance industry benefits from an aging U.S. population, rising healthcare costs driving Medicare supplement demand, and growing awareness of retirement income needs. Challenges include regulatory changes, interest rate sensitivity, competitive pressure from larger and more diversified insurers, and the vulnerability of the middle-income target demographic to economic cycles.
At $51.96, the stock trades at 20.95x trailing earnings, 1.94x book value, and 1.13x sales. Levered free cash flow yield is 21.25% but the high debt/equity (172%) constrains how much of that FCF translates to shareholder returns. A margin of safety depends on demonstrable debt reduction, margin improvement, and organic growth -- not on assuming the current multiple will expand.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| CNO stock price | $51.96 close on July 10, 2026 | Yahoo Finance | July 12, 2026 |
| Market cap | $4.85 billion | Yahoo Finance | July 12, 2026 |
| Enterprise value | $8.02 billion | Yahoo Finance | July 12, 2026 |
| Trailing P/E | 20.95x | Yahoo Finance; financial_rigor.py verification | July 12, 2026 |
| EPS (TTM) | $2.48 | Yahoo Finance | July 12, 2026 |
| Revenue (TTM) | $4.51 billion | Yahoo Finance | July 12, 2026 |
| Net income (TTM) | $245.5 million | Yahoo Finance | July 12, 2026 |
| Profit margin | 5.44% | Yahoo Finance | July 12, 2026 |
| Price / Book (mrq) | 1.94x | Yahoo Finance | July 12, 2026 |
| ROE (TTM) | 9.76% | Yahoo Finance | July 12, 2026 |
| Total cash (mrq) | $1.41 billion | Yahoo Finance | July 12, 2026 |
| Debt / Equity (mrq) | 172.19% | Yahoo Finance | July 12, 2026 |
| Levered free cash flow (TTM) | $1.03 billion | Yahoo Finance | July 12, 2026 |
| Forward dividend and yield | $0.72 per share (1.39%) | Yahoo Finance | July 12, 2026 |
| Beta (5Y monthly) | 0.82 | Yahoo Finance | July 12, 2026 |
| 52-week range | $35.24 to $53.55 | Yahoo Finance | July 12, 2026 |
| Share count (est.) and market-cap check | Approx. 93.3 million shares; $51.96 x 93.3M = $4.85B | Yahoo Finance and financial_rigor.py calculation | July 12, 2026 |
| Q1 2026 revenue | $1.03 billion | Yahoo Finance earnings data | July 12, 2026 |
| Q1 2026 net income | $101.3 million | Yahoo Finance earnings data | July 12, 2026 |
This CNO AI stock analysis is an informational research tool only and is not investment advice, a recommendation, or a guarantee of future returns. Forecast scenarios use available public data as of July 12, 2026 and can be wrong if earnings, claims experience, interest rates, valuation multiples, or market conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
